ESC 365 - Novel multidisciplinary cardiometabolic clinic in a UK tertiary cardiology centre: early activity, interventions and potential for cardiovascular risk optimisation

ESC Premium Access

Novel multidisciplinary cardiometabolic clinic in a UK tertiary cardiology centre: early activity, interventions and potential for cardiovascular risk optimisation

Session: Risk Factors and Prevention ePosters

Topic: Diabetes and the Heart

Speaker: Doctor R. Narain (London, GB)

Event: ESC Congress 2021 - The Digital Experience

Congress Presentation

About the speaker

Doctor Rajay Narain

St George's University of London, London (United Kingdom of Great Britain & Northern Ireland)

0 follower

224 more presentations in this session

High risk characteristics in patients with hypertrophic cardiomiyopathy for predicting cardiovascular events

Speaker: Doctor B. Keskin (Istanbul, TR)

Cardiac biomarkers as prognosticators among SARS-CoV-19 patients in a tertiary hospital in Philippines

Speaker: Doctor R. Ong (Makati, PH)

Prevalence of atherosclerosis risk factors in Egyptian patients with acute coronary syndromes; final data of the nationwide cross-sectional CardioRisk project

Speaker: Doctor A. Bendary (Benha, EG)

SF-12 Physical and Mental Health Scales predict cardiovascular events after hospitalization

Speaker: Mr R. Gascuena (Leganes, ES)

Comparison of traditional versus artificial intelligence based coronary artery disease risk prediction scores in young patients with acute coronary syndrome

Speaker: Doctor S. Vohra (Lucknow, IN)

Access the full session

Risk Factors and Prevention ePosters

Speakers: Doctor R. Narain, Doctor B. Keskin, Doctor R. Ong, Doctor A. Bendary, Mr R. Gascuena...

About the event

ESC Congress 2021 - The Digital Experience

27 August - 30 August 2021

Sessions Presentations

Congress

Related content

ESC Premium Access

Future treatments for lipoprotein(a).

27 August 2021

ESC Premium Access

Current treatment for elevated lipoprotein(a).

27 August 2021

ESC Premium Access

Cardiovascular protection by combination of the selective nonsteroidal MR antagonist finerenone and the SGLT2 inhibitor empagliflozin in a preclinical model of hypertension-induced end-organ damage

27 August 2021

ESC 365 is supported by